PeerView Live

@PeerView

CME/MOC/NCPD/AAPA/IPCE-Certified Live Activity

BU Chobanian & Avedisian School of Medicine

COPD ECHO® Program

Transforming Patient Care With the Use of Targeted Biologic Therapy

Join us for this live, virtual COPD ECHO® Program on the dates below, from 7:00–8:00 PM ET

Thursday, February 5, 2026 | Tuesday, February 24, 2026 | Thursday, March 26, 2026 | Tuesday, April 14, 2026

Meet Your Presenters

CO-CHAIR & PRESENTER

MeiLan K. Han, MD, MS
University of Michigan
Ann Arbor, Michigan

CO-CHAIR & PRESENTER

Fernando J. Martinez, MD, MS
UMass Chan Medical School
Worcester, Massachusetts

CO-CHAIR & PRESENTER

Claire Murphy, RN, MSN, FNP-BC
Boston University School of Medicine
Boston, Massachusetts

CO-CHAIR & PRESENTER

Sohera N. Syeda, MD
Boston University School of Medicine
Boston, Massachusetts
VA Boston Healthcare System
West Roxbury, Massachusetts

PRESENTER

Arianne K. Baldomero, MD, MS
University of Minnesota
Minneapolis VA Health Care System
Minneapolis, Minnesota

PRESENTER

Molly Grove, MD
PeaceHealth Family Medicine of Southwest Washington Residency
Vancouver, Washington

PRESENTER

Alanna Kavanaugh, EdD(c), APRN, FNP-BC, CNE, CHSE, FCCP, FNYAM, FFNMRCSI
University of Mount Saint Vincent
New York, New York

PATIENT

Krissey Bee
Patient



Register online: PeerView.com/T2inCOPD-ECHO

Key Reasons to Attend

- Learn about the role that type 2 inflammation plays in COPD and which patients might benefit from biologic therapies
- Get up to speed on the latest clinical evidence on T2i-targeted biologic agents in the treatment of COPD
- Hear strategies for creating personalized care plans for your patients, incorporating an interprofessional care team

Pre-Register Now!

COPD ECHO® Program | 7:00–8:00 PM ET

ECHO® Sessions

All sessions will be held from 7:00–8:00 PM ET

- **Thursday, February 5, 2026:** Precision Therapy in COPD: Targeting Type 2 Inflammation
- **Tuesday, February 24, 2026:** An Individualized Approach to Type 2 Inflammation–Driven COPD Care
- **Thursday, March 26, 2026:** Selecting the Right Biologic for the Right Person With COPD
- **Tuesday, April 14, 2026:** Practical Considerations for Targeted Biologic Therapy in COPD

Register Today!

Activity Description

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation and inflammation, imposing a substantial burden on both people living with the disease and the healthcare system. While standard COPD treatment includes inhaled long-acting bronchodilators and steroids, many people with COPD continue to experience poor symptom control and frequent exacerbations.

In up to 40% of people with COPD, type 2 inflammation (T2i) is a critical driver of disease. People with T2i-driven COPD are at increased risk of exacerbations, thereby increasing the risk of subsequent exacerbations, accelerated lung function decline, and death. Thus, therapeutic advancements are shifting treatment away from a one-size-fits all model to include biologic therapies that target the underlying inflammatory pathway of COPD and provide safe, tolerable treatment options with proven efficacy in improving symptoms and overall quality of life.

With the aim of increased recognition of the T2i pathway and guideline recommendations, PeerView has prepared a series of expert discussions on the use of biologic therapy for COPD management, as well as developing optimal personalized care plans for patients living with the disease. Register now and join us for an expert review of the use of biologics to target T2i and strategies to craft individualized care plans for your patients.

Target Audience

This activity has been designed to meet the educational needs of pulmonologists, specialty advanced practice clinicians, and other healthcare professionals involved in the care of people with COPD.

Educational Objectives

Upon completion of this activity, participants should be better able to:

- Discuss the role of T2i in COPD and the mechanistic rationale for using biologic therapy
- Summarize the latest clinical evidence supporting the role of T2i-targeted biologic strategies in the treatment of people with COPD
- Identify people with COPD who would benefit from treatment with targeted biologic therapy based on the latest evidence, eosinophil levels, and treatable traits
- Develop personalized, team-based care plans for people with COPD that incorporate biologic therapy and shared decision-making, with attention to patient preferences, treatment goals, and AE management

Accreditation, Credit, and Support

PVi PeerView INSTITUTE FOR MEDICAL EDUCATION

BU Chobanian & Avedisian School of Medicine

This activity is developed as a joint collaboration between Boston University Chobanian & Avedisian School of Medicine and PVI, PeerView Institute for Medical Education.

In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Please note that 4.0 credits are based on participation in all four activities.

Physicians

Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 4.0 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By participating and claiming credit, you agree to BU sharing your information with ACCME PARS the data conduit to the ABIM.

Nurses

Nursing Contact Hours: 4.0 of which 4.0 are eligible for pharmacology credit.

Please note that 4.0 credits are based on participation in all four activities.

Physician Assistants

Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 4.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Support

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.